1. ICH S7A: Safety Pharmacology Studies for Human Pharmaceuticals. CPMP/ICH/539/00;Anon,2001
2. ICH S7B: The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarisation (QT Interval Prolongation) by Human Pharmaceuticals. CPMP/ICH/423/02;Anon,2005
3. ICH Topic E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-arrhythmic Drugs. CHPM/ICH/2/04;Anon,2005
4. EvaluatePharma® World Preview 2017, Outlook to 2022;Anon,2017
5. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors;Beerepoot;J. Clin. Oncol.,2006